« Previous  |  Next »

Public Database Is Urged to Monitor Drug Safety

What could be done to prevent another Vioxx? This pain medication for arthritis became a blockbuster after its introduction in 1999, only to be taken off the market in 2004 when a study linked the drug to an increased risk of heart attack and strokes. ...

From NATASHA SINGER, The New York Times,  23 Nov 2009

Related Topics: Merck & Company, Inc.,  U.S. Congress,  Food and Drug Administration,  University of California,  Bayer

Artery Disease in Some Very Old Patients

The Book of Exodus in the King James translation of the Bible describes a pharaoh who “hardened his heart” against the exodus of the Jews from ancient Egypt. But if a research letter published last week in The Journal of the American Medical ...

From NATASHA SINGER, The New York Times,  23 Nov 2009

Related Topics: American Medical Association,  University of California,  Johns Hopkins

Insurers Unlikely to Alter Policies in the Debate Over Mammograms

Elizabeth Sanders, a radiologist in Auburn, Wash., checks a digital mammogram. And that was even before new guidelines this week recommended that women wait longer to begin getting mammograms and have fewer of them. The business of providing ...

From NATASHA SINGER AND REED ABELSON, The New York Times,  18 Nov 2009

Related Topics: Hologic, Inc.,  Kathleen Sebelius,  WellPoint, Inc,  Aetna Inc.,  UnitedHealth Group

Investors Seem Unshaken After Study of Merck Drug

ORLANDO, Fla. Such are the fortunes of the Merck cholesterol drug Zetia that a study reporting a lack of medical benefit is considered good news for investors. The results of the long-awaited scientific study, released Sunday, could have been worse for ...

From NATASHA SINGER, The New York Times,  16 Nov 2009

Related Topics: Merck & Company, Inc.,  American Heart Association,  Abbott Laboratories,  New England Journal of Medicine

Study Raises Questions About Cholesterol Drug’s Benefit

ORLANDO, Fla. For patients taking a statin to control high cholesterol, adding an old standby drug, niacin, was superior in reducing buildup in the carotid artery to adding Zetia, a newer drug that reduces bad cholesterol, according to a new study. ...

From NATASHA SINGER, The New York Times,  15 Nov 2009

Related Topics: Merck & Company, Inc.,  Schering Plough Corp,  Food and Drug Administration,  Johns Hopkins University,  Abbott Laboratories

Seeking a Shorter Path to New Drugs

WHAT’S smaller than a breadbox, can cost $800 million or more, and takes more than eight years to research and develop? A new medicine, according to data from the Tufts Center for the Study of Drug Development in Boston. And that’s just for traditional ...

From NATASHA SINGER, Boston Globe,  15 Nov 2009

Related Topics: Merck & Company, Inc.,  Massachusetts Institute of Technology,  Harvard Business School

Slipstream: Seeking a Shorter Path to New Drugs

Deborah Nightingale, left, and Dr. Gigi Hirsch, both of M.I.T., see a value in the streamlining of drug research. WHAT’S smaller than a breadbox, can cost $800 million or more, and takes more than eight years to research and develop? And that’s just ...

From NATASHA SINGER, The New York Times,  14 Nov 2009

Related Topics: Merck & Company, Inc.,  Massachusetts Institute of Technology,  Harvard Business School

Cholesterol Study Vital for Merck

Some of Wall Street’s leading drug industry analysts are scheduled to fly to Orlando, Fla., on Sunday afternoon. A junket to SeaWorld it is not. For top analysts from investment banks, including JPMorgan and Credit Suisse, or some of their minions, the ...

From NATASHA SINGER, The New York Times,  12 Nov 2009

Related Topics: Merck & Company, Inc.,  American Heart Association,  Schering Plough Corp,  Food and Drug Administration,  Pfizer Inc.

Sought-After Speaker, With Script Outlines From Eli Lilly

In the first half of this year, the drug giant Eli Lilly paid 3,971 doctors and other medical professionals an average of about $11,230 each. The payments were for participating in an average of 12 speaking or consulting engagements during those six ...

From NATASHA SINGER, The New York Times,  4 Nov 2009

Related Topics: AstraZeneca PLC,  Bristol-Myers Squibb,  Pfizer Inc.

Health Bills Aim a Light on Doctors’ Conflicts

As part of the health care overhaul under consideration by Congress, lawmakers have included so-called sunshine provisions intended to shed light on the financial relationships between the medical industry and doctors. The targets are common business ...

From NATASHA SINGER, The New York Times,  3 Nov 2009

Related Topics: U.S. Congress,  U.S. Senate,  National Institutes of Health,  Institute of Medicine,  U.S. Democratic Party

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry